MDB Capital

MDB's President & Chief Market Strategist Lou Basenese will be be speaking at the?MoneyShow Alternative Investing Virtual Expo on Nov. 13 at 2:45 pm ET. Register here to listen: https://lnkd.in/e7MpDCmV #Alternatives #innovation #tech #publicventure #venturecapital

MDB Vested Interests - Traditional Venture vs. Public Venture MDB Capital President & Chief Market Strategist?Lou?Basenese sat down with?Dave Berkus, TCA Venture Group Chairman Emeritus?and?Managing Director of TCA ACE?Funds, to exchange insights on these approaches to venture-stage investing. Watch episode 9 here: https://lnkd.in/gVw_f2Gg

Join us on?Monday,?October 21, at 12:00 PM?ET?when?MDB Capital's Lou Basenese?welcomes?Dave Berkus, TCA Venture Group Chairman Emeritus and "Super Angel"?to discuss?Traditional Venture vs Public Venture. REGISTER HERE: https://lnkd.in/eSMumTJC

MDB Vested Interests – Episode 8: ClearSign Technologies Corporation (Nasdaq: CLIR) MDB Capital?Capital?President & Chief Market Strategist?Lou Basenese?Basenese and Jim Deller discussed how ClearSign Technologies latest commercial developments are accelerating their emerging leadership position in the industrial combustion and sensing technologies market. Recorded September 12, 2024. WATCH VIDEO: https://lnkd.in/gPPEYsFQ ClearSign Technologies Corporation (Nasdaq: CLIR) designs and develops products and technologies that enhance the performance of combustion systems and fuel safety systems in a broad range of markets, including the energy (upstream oil production and down-stream refining), commercial/industrial boiler, chemical, petrochemical, transport, and power industries.

REPLAY:?Invizyne Technologies IPO Update Call MDB Capital Co-Founder & CEO Christopher Christopher Marlett, President & Chief Market Strategist Lou Basenese and Chief Legal Officer Mo Hayat provide the latest status on the Invizyne Technologies IPO, filing of an updated registration statement, addition of a Long Term Investor Right (LTIR) and the anticipated closing. September 11, 2024 WATCH VIDEO: https://lnkd.in/gsCq8gKF Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.

Please join us on?Thursday,?September 12, at?4:00pm ET?when?MDB Capital President & Chief Market Strategist?Lou Basenese?visits with ClearSign Technologies CEO Dr. Jim Deller. ? Lou and Jim will explore how ClearSign Technologies latest commercial developments are accelerating their emerging leadership position in the industrial combustion and sensing technologies market. REGISTER HERE. https://lnkd.in/dGuQYdge ClearSign Technologies Corporation designs and develops products and technologies that enhance the performance of combustion systems and fuel safety systems in a broad range of markets, including the energy (upstream oil production and down-stream refining), commercial/industrial boiler, chemical, petrochemical, transport, and power industries. MDB recently completed secondary financing for ClearSign.

National Renewable Energy Lab (NREL) working with Invizyne MDB Capital President & Chief Market Strategist Lou Basenese hosts a conversation with Yannick Bomble, PhD Bomble, Ph.D., Research Group Director and Distinguished Principal at the National Renewable Energy Laboratory (NREL) and Tyler Korman, Founder and VP of Research at Invizyne to explore National Renewable Energy Laboratory’s “Advancing Clean Tech to Energize the Future” project and Invizyne’s involvement in it. August 26, 2024. VIEW VIDEO HERE: https://lnkd.in/e_XRfbuA

REPLAY: Invizyne IPO – Conversation with?Zachary Karl, Ph.D., VP Business Development In response to investor requests for more information on Invizyne’s business development strategy and activities,?MDB Capital?President and Chief Market Strategist?Lou Basenese?talked with?Zachary Karl, Ph.D., VP Business Development?on July 29, 2024. WATCH REPLAY HERE: https://lnkd.in/gsbajaZc Dr. Karl has been spearheading Invizyne’s growth trajectories and strategic partnerships since September 2023, after spending the previous decade in pivotal roles in business development at Ginkgo Bioworks Holdings, Inc. (DNA), POET Technologies Inc. (POET), and SAB Biotherapeutics, Inc. (SABS). Invizyne?is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO).?MDB Capital?is acting as the sole underwriter for the offering.

REPLAY: Invizyne IPO - KOL Call with Dr. James J. Lalonde MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. Jim Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024. WATCH REPLAY HERE: https://lnkd.in/gdNGdCNq Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.

NEWS:?ClearSign Technologies Announces Order for Multi Heater Project for Texas Petrochemical Facility ClearSign Technologies Corporation (Nasdaq: CLIR) announces that it has received the initial engineering order from engineering and heater manufacturer Birwelco USA Inc. (a BIH Group company) as the first phase of a project to retrofit four process heaters with a total of 26 ClearSign Core? burners to be installed in the Gulf Coast facility of a Fortune 500 global chemical company. READ THE FULL PRESS RELEASE: https://lnkd.in/gkPRdUG8 NOTICE: In the last 12 months, MDB Capital was compensated for acting as the sole underwriter and placement agent for a secondary offering and private placement for ClearSign.?MDB Capital and its beneficial owners currently own common stock and warrants to purchase common stock of ClearSign. Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product.